CD4 and neoplasm: Anti-Nrp-1 not only allowed the increased expansion of tumor-derived CD4+CD8a− T cells(Fig. 5B), but it also activated tumor-derived CD4+ T cells (CD4+CD69+) in IL-10−/− and WT B16/F10 mice (Fig. 5C).